Beniamin Philippus Levy Dr

Dr. Benjamin Levy est oncologus thoracicus medicinae qui etiam moderatori clinici medicinae oncologiae inservit Johns Hopkins Sidney Kimmel Cancer Centrum in Hospitali Sibley Memorial et socius oncologiae apud Johns Hopkins Scholam Medicinae Universitatis professor. Johns Hopkins Sidney Kimmel Cancer Centre ex Hospitali Sibley operatur.

Dr. Levy is a clinician scientist who is interested in novel immunotherapeutic treatments for patients with advanced pulmonis cancer,, as well as biomarkers that help identify those patients who are more likely to respond to such medicines. He specialises in thoracic malignancies such as non-small cell lung cancer, small cell lung cancer, thymic malignancies, and caput et collum cancer.

Dr. Levy graduated from the Medical College of Georgia. He completed an internal medicine residency at Georgetown University Hospital, followed by a hematology/oncology fellowship at New York Presbyterian/Weill Cornell Medical Centre, where he received the Department of Medicine Research Fellow of the Year Award and the 2009 American Society of Clinical Oncology Young Investigator Award for his prostate cancer clinical research. Dr. Levy previously worked as an assistant professor at the Icahn School of Medicine, as the medical director of thoracic oncology for Mount Sinai Health Systems, and as the associate director of Mount Sinai Hospital’s Cancer Orci iudiciis Officium.

Dr. Levy in plurimis commissionibus Americanis Societati Fusce Oncologiae (ASCO) inservivit et nunc editor socius universitatis ASCO Committee adest. In tabula editoriali Acta Oncologia Fusce per duos annos ministravit et ad hoc CENSOR adiectis in actis publici iuris est, ut Fuscus Lung Cancer, The Oncologist, et scopum Onco. Dr. Dilectus nuper electus est unus ex 15 oncologists in patria, ut participet praestanti ASCO Principatus progressionis programmatis, quod intendit invenire et instituendi duces futuros ASCO. Dr. Levy etiam inservit Societati Respiratorii Committee, IASLC Committee Staging, ac IASLC Tutela & Societas Committee, praeter actiones suas ASCO.

• Pulmonis cancer
• immunotherapy

Becker DJ, Wisnivesky JP, Grossbard ML, Chachoua A, Camidge DR, dilectus BP. "Survival of Asian Feminae Cum Provectus Lung Cancer in aetate Tyrosine Kinase Inhibitor Therapy." Clin Lung Cancer. 2017 Jan;18(1): e35-e40. doi: 10.1016/j.cllc.2016.08.008.

dilectus BP, Rao P, Becker DJ, Becker K. "Adortus target movens: Intellectus resistentia et progressionem administrandi in EGFR-positivi pulmonis Cancer aegroti cum inhibitoribus tyrosinis Kinase tractantur." oncology (Williston Park). 2016 Iul;30(7):601-12. Recensio.

dilectus BP, Chioda MD, Herndon D, Longshore JW, Mohamed M, Ou SH, Reynolds C, Singh J, Wistuba II, Bunn PA Jr, Hirsch FR. "Molecularis Testis curationi metastaticae Non-parvae Cellae pulmonis Cancri: Quomodo ad exsequendam evidentiam Ex Commendatione". oncologist. 2015 Oct;20(10):1175-81. doi: 10.1634/theoncologist.2015-0114.

Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, Otterson GA, Campos LT, Gandara DR, dilectus BP, Nair SG, Zalcman G, Lupus J, Souquet PJ, Baldini E, Cappuzzo F, Chouaid C, Dowlati A, Sanborn R, Lopez-Chavez A, Grohe C, Huber RM, Harbison CT, Baudelet C, Lestini BJ, Ramalingam SS. . "Actio et salus nivolumab, inhibitoris anti-PD-I immunis, aegris cum progressu, refractione squama cancer pulmonis non-parvus cell (CheckMate 1): Phase 063, brachii iudicii. Lancea Oncol. 2015 Mar;16(3):257-65. doi: 10.1016/S1470-2045(15)70054-9.

dilectus BP, Becker DJ. "Tempus low-dosis computatus tomographiam protegendorum nunc est: perspectiva medicorum oncologist." oncology (Williston Park). MMXIV Nov; XXVIII (2014): 28-11. Abstracta nulla available.